Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - 44670 - bladder instillation, barrier - procedure pack consisting of a clear plastic pre-filled syringe containing a sterile aqueous solution of hyaluronic acid sodium salt (1.6%), sodium chondroitin sulphate (2%) and calcium chloride administered as a bladder instillation via connection to a catheter using the leur lock adaptor and the ialuadapter included in the pack. the ialuadapter allows for administration by either the patient or healthcare professional. ialuril is indicated to re-establish the glycosaminoglycan layers (gags) of the urothelial vesical tissue in cases in which their loss can cause frequent and recurring problems such as painful bladder syndrome (pbs), interstitial cystitis, treatment and prevention of recurrent urinary tract infection, cystitis as a result of bacillus calmette ? guerin therapy, or chemical and radiation therapy. ialuril is also indicated in the cases where the loss of the glycosaminoglycan layers (gags) is associated with forms of chronic inflammation, in which their composition and integrity appears compromised in different ways.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - 44670 - bladder instillation, barrier - clear plastic pre-filled syringe containing a sterile aqueous solution of hyaluronic acid sodium salt (1.6%), sodium chondroitin sulphate (2%) and calcium chloride administered as a bladder instillation via a catheter. ialuril prefill is indicated to re-establish the glycosaminoglycan layers (gags) of the urothelial vesical tissue in cases in which their loss can cause frequent and recurring problems such as painful bladder syndrome (pbs), interstitial cystitis, treatment and prevention of recurrent urinary tract infection, cystitis as a result of bacillus calmette ? guerin therapy, or chemical and radiation therapy. ialuril prefill is also indicated in the cases where the loss of the glycosaminoglycan layers (gags) is associated with forms of chronic inflammation, in which their composition and integrity appears compromised in different ways.

Australia - English - Department of Health (Therapeutic Goods Administration)

biomarin pharmaceutical australia pty ltd - galsulfase, quantity: 5 mg - injection, concentrated - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; dibasic sodium phosphate heptahydrate; polysorbate 80; sodium chloride - for the long-term enzyme replacement therapy in patients with mucopolysaccharidosis vi (mps vi - n acetylgalactosamine 4-sulfatase deficiency)

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

optima consumer health ltd - glucosamine sulfate - oral tablet

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

shire pharmaceuticals ltd - idursulfase - solution for infusion - 2mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

health+plus ltd - ascorbic acid; glucosamine sulfate - oral tablet

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - laronidase 0.58 mg/ml (rch) - concentrate for infusion - 500 u/5ml - active: laronidase 0.58 mg/ml (rch) excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - aldurazyme is indicated as long-term enzyme replacement therapy in patients with mucopolysaccharidosis i (mps i; alpha-l-iduronidase deficiency) to treat the non-neurological manifestations of the disease.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

aspen notre dame de bondeville - nadroparin calcium - solution for injection - 2850iu axa/0,3ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

aspen notre dame de bondeville - nadroparin calcium - solution for injection - 5700iu axa/0,6ml

European Union - English - EMA (European Medicines Agency)

ultragenyx germany gmbh - vestronidase alfa - mucopolysaccharidosis vii - enzymes - mepsevii is indicated for the treatment of non-neurological manifestations of mucopolysaccharidosis vii (mps vii; sly syndrome).